While its net profit, revenue and earnings before interest tax depreciation and amortisation (EBITDA) increased, its margins contracted.
Rossari Biotech's net profit was up 3.2% at ₹32.7 crore from ₹31.7 crore int he previous year.
Its revenue witnessed a 13.4% increase to ₹581.6 crore from ₹512.7 crore in the third quarter of the previous fiscal.
The company's EBITDA also increased 6.3% annually to ₹68.8 crore from ₹64.7 crore.
However, its margin contracted to 11.8% from 12.6% in the year-ago period.
Shares of Rossari Biotech ended the previous session nearly 1% lower at ₹534.5 apiece. The stock has declined 33.6% in the past year.
Also Read: Punjab & Sind Bank Q3 Results | Profit rises 19% YoY, asset quality improves
/images/ppid_59c68470-image-176865003115368906.webp)

/images/ppid_a911dc6a-image-17686491335952064.webp)


/images/ppid_a911dc6a-image-176864803457262432.webp)

